Evoke Pharma Addresses FDA Update on Domperidone Supply and Highlights GIMOTI as the Only Approved Treatment for Gastroparesis
Evoke Pharma highlights GIMOTI's role amid FDA's domperidone supply concerns, emphasizing its benefits for gastroparesis patients.Quiver AI SummaryEvoke Pharma, Inc. announces its commitment to addressing...
Evoke Pharma Receives Patent Allowances Expanding Intellectual Property for GIMOTI® Nasal Spray Treatment for Gastroparesis
Evoke Pharma received patent allowances for GIMOTI nasal spray, enhancing its protection for treating diabetic gastroparesis.Quiver AI SummaryEvoke Pharma, Inc., a specialty pharmaceutical company focusing...